Saladax Develops First-Ever Rapid Test for an Antipsychotic Drug Using a Single Drop of Blood to Aid Psychiatrists in the Treatment of Schizophrenia
5.9.2019 16:30:00 EEST | Business Wire | Press release
Saladax Biomedical today announced that its MyCare Insite Clozapine Test is now CE marked for use on the MyCare Insite. The MyCare Insite Clozapine Test is the first and only rapid point-of-care test CE marked to aid mental health professionals in the treatment and monitoring of patients with schizophrenia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190905005085/en/
The MyCare Insite Clozapine Test delivers accurate and precise clozapine blood levels comparable to laboratory results. Psychiatrists need immediate information to make informed decisions during a patient visit. The MyCare Insite Clozapine Test addresses this unmet medical need by providing answers in only six minutes. Clinicians, in consultation with their patients, can use these results to make real-time adjustments to better manage their patients.
"Mental health professionals have very few tools to aid in patient treatment; as a result, patients are suffering. The MyCare Insite Clozapine Test provides clinicians a first of its kind device. The test is evidence of how Saladax is once again setting new standards for innovation in the treatment and monitoring of patients," said Dr. Salvatore Salamone, CEO and Founder of Saladax Biomedical. "We are changing psychiatry with a single drop of blood.”
ABOUT PSYCHOSIS
Psychosis is a condition that affects the way your brain processes information. It causes you to lose touch with reality. Psychotic disorders, like schizophrenia, involve psychosis that usually affects you for the first time in the late teen years or early adulthood. Young people are especially at risk, but doctors don’t know why.
ABOUT THE MyCARE INSITE CLOZAPINE TEST
The MyCare Insite Clozapine Test is intended for the in vitro quantitative measurement of clozapine in human capillary finger blood using the MyCare Insite.
ABOUT SALADAX
Founded in 2004, Saladax Biomedical, Inc. is a privately held company headquartered as an anchor tenant at Ben Franklin TechVentures® located on Lehigh University’s campus in Bethlehem, PA.
Saladax develops rapid blood tests for point-of-care and for laboratory analysers for use in psychiatry and oncology. The Saladax MyCare Psychiatry line provides drug levels for greater insight into patient adherence and possible causes of treatment failures. These tests enable psychiatrists to more accurately assess adherence and better adjust medication dosing. Saladax believes that truly personalized medicine can only exist when the right drug is taken at the right dose. Our diagnostic reagent kits are distributed worldwide and are pending approval in the United States. Saladax is ISO 13485:2016 certified.
For more information, visit Saladax.com or MyCareTests.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190905005085/en/
Contact information
Saladax Biomedical, Inc.
Salvatore Salamone, Ph.D., 610-419-6731
ssalamone@saladax.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gustave Roussy and One Biosciences Partner to Bring Single Cell to Clinical Practice for Precision Oncology19.5.2026 14:02:00 EEST | Press release
Gustave Roussy partners with One Biosciences, a techbio company that harnesses single cell technology and AI to develop advanced precision diagnostics. The collaboration aims to further demonstrate the feasibility and impact of integrating single nuclei transcriptomic analysis into the patient care pathway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519540709/en/ Gustave Roussy, Europe’s leading cancer center, is teaming up with One Biosciences to harness the cutting-edge potential of OneMapTM, the single-cell and AI-powered solution helping to enhance precision oncology solutions. By analyzing anonymized frozen samples across four cancer indications, One Biosciences will deploy OneMapTM to generate ultra-high-resolution single-cell data, unlocking the hidden functional diversity of each tumor with unparalleled precision. Prof. Sophie Postel-Vinay, oncologist at Gustave Roussy, team leader in Inserm unit U981 at Gusta
Venionaire Capital Mandated to Structure KISAB’s Next Growth Round19.5.2026 13:41:00 EEST | Press release
Venionaire Capital has been mandated by Kiselkarbid i Stockholm AB (“KISAB”) to structure and support the company’s next growth round. The mandate includes investor relations, investor communications and strategic financing preparation, targeting growth private equity and strategic investors. KISAB is a Sweden-based silicon carbide semiconductor materials company focused on advanced SiC substrates for power electronics. The company publicly highlights its 8-inch BPD-free n-type silicon carbide wafers, with the 8-inch platform representing an important technological step for next-generation high-performance power electronics. KISAB has previously attracted approximately EUR 24 million across several financing rounds. Publicly named investors include Fairpoint Capital, Industrifonden and Ingka GreenTech. Venionaire Capital will now support the company in sharpening its equity story, structuring its investor dialogue and positioning the opportunity for the next phase of growth, which is t
motif Launches Clarity, a First-of-Its-Kind AI Financial Intelligence System19.5.2026 13:39:00 EEST | Press release
motif, the AI wealth advisory company backed by Liminal (a venture creation group founded by Temasek), today launched Clarity, an AI financial intelligence system that tracks how markets, assets and financial relationships connect, and how and why they change over time, building enriched connections that deliver the kind of structured, sourced insight that financial institutions have never had, even with dedicated analyst teams. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511241653/en/ motif Launches Clarity, a First-of-Its-Kind AI Financial Intelligence System Financial institutions integrate Clarity into their products so customers can make better-informed investment decisions, while analysts and product teams use it to track market shifts and plan accordingly. Informed investors engage more and stay longer, and for the institutions serving them, that engagement translates directly into retention and profitability. M
Axelspace Announces Launch of Seven GRUS-3 Earth Observation Microsatellites, No Earlier Than July 202619.5.2026 11:30:00 EEST | Press release
Axelspace Corporation, a leading developer and operator of microsatellites dedicated to realizing its vision of “Space within Your Reach,” announced today that GRUS-3, a set of seven next-generation Earth observation microsatellites, is scheduled to be launched no earlier than July 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519449959/en/ Seven flight model of GRUS-3 next-generation Earth observation microsatellites ©Axelspace The seven GRUS-3 microsatellites will launch aboard the Transporter-17 rideshare mission via Exolaunch, a global leader in launch mission management, satellite integration, and deployment services, from Vandenberg Space Force Base in California, USA. We currently operate five optical Earth observation microsatellites, GRUS-1, under our Earth observation data service, AxelGlobe. With the launch of its successor, GRUS-3, it will expand its satellite constellation to more than 10 satellites. E
Money20/20 Europe Announces Powerhouse Speaker Lineup Featuring Leaders from Klarna, BBVA, ABN AMRO, Mastercard, eToro, and Revolut19.5.2026 11:10:00 EEST | Press release
Money20/20, the world’s leading fintech show and the place where money does business, today announced a stellar line-up of speakers for Money20/20 Europe happening on June 2-4 at the RAI in Amsterdam. The show will feature 450+ speakers across six stages, exploring the forces redefining global finance through AI innovation, digital assets, and regulatory transformation. Newly confirmed speakers include some of the most influential voices shaping the future of payments, banking, and financial services: Sebastian Siemiatkowski, Co-Founder and CEO, Klarna. A pioneer in the buy now, pay later revolution, Siemiatkowski has transformed consumer payments and continues to drive innovation in embedded finance and AI-powered shopping experiences. Onur Genç, CEO, BBVA. Leading one of Europe's most digitally advanced banks, Genç is at the forefront of banking transformation, leveraging data, technology, and customer-centric strategies to redefine financial services. Marguerite Bérard, Chief Execut
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom